Lung Biotechnology
North America, Maryland, United States, Silver Spring
Description
Lung Biotechnology PBC is engaged in the research and development, and marketing of therapies for pulmonary arterial hypertension (PAH)
Investor Profile
Lung Biotechnology has made 4 investments, with 0 in the past 12 months and 50% as lead.
Stage Focus
- Corporate Round (50%)
- Private Equity (25%)
- Series F (25%)
Country Focus
- United States (100%)
Industry Focus
- Health Care
- Medical
- Medical Device
- Service Industry
- Wellness
- Biotechnology
- Renewable Energy
FAQ
Frequently Asked Questions
Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.
'%3e%3cpath fill='%23012169' d='M0 0v30h60V0z'/%3e%3cpath stroke='%23fff' stroke-width='6' d='m0 0 60 30m0-30L0 30'/%3e%3cpath stroke='%23C8102E' stroke-width='4' d='m0 0 60 30m0-30L0 30' clip-path='url(%23b)'/%3e%3cpath stroke='%23fff' stroke-width='10' d='M30 0v30M0 15h60'/%3e%3cpath stroke='%23C8102E' stroke-width='6' d='M30 0v30M0 15h60'/%3e%3c/g%3e%3c/svg%3e)
